These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 1635498)
1. Immunosuppression in transplantation. Russ GR Med J Aust; 1992 Aug; 157(3):198-203. PubMed ID: 1635498 [No Abstract] [Full Text] [Related]
2. Nursing implications of immunosuppression in transplantation. Shaefer M; Williams L Nurs Clin North Am; 1991 Jun; 26(2):291-314. PubMed ID: 1904575 [TBL] [Abstract][Full Text] [Related]
3. Use of antilymphocyte induction therapy in liver transplantation: A European perspective. Langrehr JM; Neuhaus PJ Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S71-84. PubMed ID: 10431020 [No Abstract] [Full Text] [Related]
4. Pancreas transplantation with ATG vs OKT3. Rosenberg L Transplant Proc; 1997 Nov; 29(7A):35S-36S. PubMed ID: 9366927 [No Abstract] [Full Text] [Related]
5. The role of immunosuppressive drugs in transplantation. Triemer H J Med Assoc Ga; 1998 Apr; 87(2):93-6. PubMed ID: 16259250 [No Abstract] [Full Text] [Related]
8. Immunosuppression is not related to the response to steroids in acute liver rejection. Bercedo J; Jiménez C; Moreno E; García MA; Palomo JC; Loinaz C; Marcello M; Moreno C; Chamorro A; Manzanera M Transplant Proc; 1995 Aug; 27(4):2328-9. PubMed ID: 7652830 [No Abstract] [Full Text] [Related]
9. Antilymphocyte-antibody prophylaxis: review of the adult experience in heart transplantation. Taylor DO; Kfoury AG; Pisani B; Hammond EH; Renlund DG Transplant Proc; 1997 Dec; 29(8A):13S-15S. PubMed ID: 9414668 [No Abstract] [Full Text] [Related]
10. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation. Klupp J; Bechstein WO; Pratschke J; Tullius SG; Gebhard A; Lobeck H; Langrehr JM; Neuhaus R; Neuhaus P Transplant Proc; 1998 Jun; 30(4):1443-4. PubMed ID: 9636585 [No Abstract] [Full Text] [Related]
11. Successful therapy of chronic renal allograft failure by enhanced immunosuppression. Kliem V; Tiroke T; Ehlerding G; Eberhard O; Behrend M; Frei U; Koch KM; Pichlmayr R; Brunkhorst R Transplant Proc; 1998 Jun; 30(4):1207-9. PubMed ID: 9636490 [No Abstract] [Full Text] [Related]
12. Evaluation of various immunosuppressive regimes in second renal transplants. Toronyi E; Remport A; Járay J; Máthé Z; Borka P; Perner F Transplant Proc; 2001 May; 33(3):2315-6. PubMed ID: 11377543 [No Abstract] [Full Text] [Related]
13. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation. Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207 [No Abstract] [Full Text] [Related]
17. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854 [TBL] [Abstract][Full Text] [Related]
18. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation. Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180 [No Abstract] [Full Text] [Related]
19. Treatment of steroid resistant acute rejection after renal transplantation. Oh CK; Kim YS; Kim MS; Kim SI; Park K Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737 [No Abstract] [Full Text] [Related]